


Jingxiao Zhang\*, Xiaoxiao Zhao and Chenyu Cai

# The crystal structure of *N*-cyclohexyl-3-hydroxy-4-methoxybenzamide, $C_{14}H_{19}NO_3$



<https://doi.org/10.1515/ncrs-2022-0066>

Received February 6, 2022; accepted March 29, 2022;  
published online April 13, 2022

## Abstract

$C_{14}H_{19}NO_3$ , monoclinic,  $Cc$  (no. 9),  $a = 11.1235(5)$  Å,  $b = 15.3724(5)$  Å,  $c = 8.1110(3)$  Å,  $\beta = 109.3980(10)$ °,  $V = 1308.21(9)$  Å<sup>3</sup>,  $Z = 4$ ,  $R_{gt}(F) = 0.0300$ ,  $wR_{ref}(F^2) = 0.0703$ ,  $T = 170$  K.

CCDC no.: 2162880

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

## Source of material

The 3-hydroxy-4-methoxybenzoic acid (10 mmol), cyclohexylamine (10.4 mmol), and *N,N*-diisopropylethylamine (20 mmol) were dissolved in DMF (20 mL) initially, and 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HATU, 10.4 mmol) was added to the solution with stirring. After the mixture was stirred for 5 h, the reaction was completed (monitored by TLC). A saturated NaCl solution (100 mL) was added, and the product was extracted with ethyl acetate (50 mL) three

**Table 1:** Data collection and handling.

Crystal:	Colorless block
Size:	0.19 × 0.12 × 0.08 mm
Wavelength:	Mo $K\alpha$ radiation (0.71073 Å)
$\mu$ :	0.09 mm <sup>-1</sup>
Diffractometer, scan mode:	D8 VENTURE, $\varphi$ and $\omega$
$\theta_{max}$ , completeness:	26.4°, 98%
$N(hkl)_{measured}$ , $N(hkl)_{unique}$ , $R_{int}$ :	5397, 2183, 0.030
Criterion for $I_{obs}$ , $N(hkl)_{gt}$ :	$I_{obs} > 2 \sigma(I_{obs})$ , 2059
$N(param)_{refined}$ :	166
Programs:	Bruker [1], Olex2 [2], SHELX [3,4]

times. The combined organics were washed with 5% citric acid, 5% NaHCO<sub>3</sub>, and H<sub>2</sub>O. Subsequently, the mixture was dried over MgSO<sub>4</sub>, filtered, and concentrated under vacuum to give the title product. Suitable crystals of the title compound were obtained by recrystallization in ethyl acetate and dried at ambient temperature for one week.

## Experimental details

Hydrogen atoms were added in their geometrically idealized positions and treated as riding models on their parent atoms with  $U_{iso}(H) = 1.2 U_{eq}(C)$ .

## Comment

Amides are common functional groups in many biologically active molecules, natural products, and polymer materials and have attracted significant interest from medicinal chemists and chemical biologists [5–7]. The arylamides have been developed for various applications due to the ease of functionalization *via* substitution of the aromatic rings and the termini of the scaffold [8]. Arylamide derivatives have been widely used to inhibit treatment-related protein–protein interactions, such as Bcl-x<sub>L</sub>/Bak [9], p53/HDM2 [10], and c-Myc-Max [11]. They also effectively inhibit the aggregation of human proteins such as islet amyloid polypeptide [12] and amyloid-β [13]. Here, we report the crystal structure of a new methoxybenzamide derivative. Similar systems have been widely studied so far [14–22].

\*Corresponding author: Jingxiao Zhang, College of Food and Medicine, Luoyang Normal University, Luoyang, China,  
E-mail: zhangjingxiao@outlook.com. <https://orcid.org/0000-0003-0986-4852>

Xiaoxiao Zhao and Chenyu Cai, College of Food and Medicine, Luoyang Normal University, Luoyang, China

**Table 2:** Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å<sup>2</sup>).

Atom	x	y	z	<i>U</i> <sub>iso</sub> */* <i>U</i> <sub>eq</sub>
C1	0.8289 (2)	0.54322 (15)	0.8073 (3)	0.0300 (5)
H1A	0.829744	0.563750	0.691953	0.036*
H1B	0.836374	0.479027	0.809599	0.036*
C2	0.9426 (2)	0.58201 (15)	0.9510 (3)	0.0342 (5)
H2A	0.947738	0.556171	1.064961	0.041*
H2B	1.022184	0.567471	0.927759	0.041*
C3	0.9306 (2)	0.67980 (16)	0.9600 (3)	0.0406 (6)
H3A	0.936580	0.706160	0.851639	0.049*
H3B	1.001976	0.702560	1.059705	0.049*
C4	0.8050 (3)	0.70588 (16)	0.9818 (3)	0.0446 (7)
H4A	0.797911	0.770094	0.979177	0.054*
H4B	0.803547	0.685583	1.096951	0.054*
C5	0.6912 (2)	0.66731 (16)	0.8376 (3)	0.0363 (5)
H5A	0.611450	0.682380	0.860001	0.044*
H5B	0.686784	0.692608	0.723536	0.044*
C6	0.7030 (2)	0.56904 (14)	0.8306 (2)	0.0264 (5)
H6	0.702083	0.544733	0.944565	0.032*
C7	0.5438 (2)	0.45542 (14)	0.7058 (2)	0.0244 (4)
C8	0.4313 (2)	0.42465 (14)	0.5572 (2)	0.0250 (5)
C9	0.3970 (2)	0.33760 (15)	0.5611 (3)	0.0297 (5)
H9	0.445840	0.301741	0.654755	0.036*
C10	0.2946 (2)	0.30240 (14)	0.4333 (3)	0.0292 (5)
C11	0.2232 (2)	0.35452 (15)	0.2931 (2)	0.0268 (5)
C12	0.2550 (2)	0.44134 (14)	0.2892 (2)	0.0289 (5)
H12	0.205877	0.477203	0.195750	0.035*
C13	0.3583 (2)	0.47678 (14)	0.4209 (2)	0.0273 (5)
H13	0.378812	0.536592	0.417306	0.033*
C14	0.0574 (2)	0.35981 (16)	0.0171 (3)	0.0389 (6)
H14A	-0.002209	0.320728	-0.066351	0.058*
H14B	0.117680	0.383832	-0.035700	0.058*
H14C	0.009878	0.407350	0.047473	0.058*
N1	0.59438 (17)	0.53236 (12)	0.6914 (2)	0.0275 (4)
H1	0.561283	0.562353	0.594380	0.033*
O1	0.58582 (15)	0.40977 (10)	0.83943 (17)	0.0294 (4)
O2	0.26862 (16)	0.21647 (11)	0.4463 (2)	0.0422 (5)
H2	0.200688	0.203312	0.366500	0.063*
O3	0.12553 (14)	0.31251 (10)	0.17128 (18)	0.0322 (4)

The figure shows the molecular configuration of the title compound. In the amide functional group, the bond lengths of C7–O1, C7–N1, and N1–C6 are 1.245(3) Å, 1.331(3) Å, and 1.465(3) Å, and the angles of O1–C7–N1 and C7–N1–C6 are 121.99(16)° and 122.59(16)°, respectively. The molecule's structure is similar to the stereo-configurations of the compounds reported in references [18–22]. Methoxy and hydroxyl groups replace hydrogen atoms on the benzene ring, and the lengths of the C–O bonds are both 1.364(3) Å. The dihedral angle between the ring C8…C13 and the mean plane of the cyclohexane

group (C1…C6) is 51.76°. The bond lengths and angles are all in the expected ranges.

**Author contributions:** All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

**Research funding:** This work was financially supported by the Key Scientific Research Projects of Colleges and Universities in Henan Province (22A430032).

**Conflict of interest statement:** The authors declare no conflicts of interest regarding this article.

## References

1. Bruker. SMART APEX-II CCD; Bruker AXS Inc.: Madison, WI, USA, 2006.
2. Dolomanov O. V., Bourhis L. J., Gildea R. J., Howard J. A. K., Puschmann H. OLEX2: a complete structure solution, refinement and analysis program. *J. Appl. Crystallogr.* 2009, **42**, 339–341.
3. Sheldrick G. M. Crystal structure refinement with SHELXL. *Acta Crystallogr.* 2015, **C71**, 3–8.
4. Sheldrick G. M. SHELXTL – integrated space-group and crystal-structure determination. *Acta Crystallogr.* 2015, **A71**, 3–8.
5. Kumari S., Carmona A. V., Tiwari A. K., Trippier P. C. Amide bond bioisosteres: strategies, synthesis, and successes. *J. Med. Chem.* 2020, **63**, 12290–12358.
6. Li G., Szostak M. Non-classical amide bond formation: transamidation and amidation of activated amides and esters by selective N–C/O–C cleavage. *Synthesis* 2020, **52**, 2579–2599.
7. de Figueiredo R. M., Suppo J.-S., Campagne J.-M. Nonclassical routes for amide bond formation. *Chem. Rev.* 2016, **116**, 12029–12122.
8. Gangarde Y. M., Das A., Ajit J., Saraogi I. Synthesis and evaluation of arylamides with hydrophobic side chains for insulin aggregation inhibition. *ChemPlusChem* 2021, **86**, 750–757.
9. Yin H., Lee G.-i., Sedey K. A., Kutzki O., Park H. S., Orner B. P., Ernst J. T., Wang H.-G., Sebti S. M., Hamilton A. D. Terphenyl-based Bak BH3 α-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. *J. Am. Chem. Soc.* 2005, **127**, 10191–10196.
10. Yin H., Lee G. i., Park H. S., Payne G. A., Rodriguez J. M., Sebti S. M., Hamilton A. D. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. *Angew. Chem.* 2005, **117**, 2764–2767.
11. Jung K.-Y., Wang H., Teriete P., Yap J. L., Chen L., Lanning M. E., Hu A., Lambert L. J., Holien T., Sundan A. Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics. *J. Med. Chem.* 2015, **58**, 3002–3024.
12. Hebda J. A., Saraogi I., Magzoub M., Hamilton A. D., Miranker A. D. A peptidomimetic approach to targeting pre-amyloidogenic states in type II diabetes. *Chem. Biol.* 2009, **16**, 943–950.
13. Kumar S., Hamilton A. D. α-helix mimetics as modulators of Aβ self-assembly. *J. Am. Chem. Soc.* 2017, **139**, 5744–5755.

14. Zhao B., Shang R., Wang G.-Z., Wang S., Chen H., Fu Y. Palladium-catalyzed dual ligand-enabled alkylation of silyl enol ether and enamide under irradiation: scope, mechanism, and theoretical elucidation of hybrid alkyl Pd(I)-radical species. *ACS Catal.* 2020, **10**, 1334–1343.
15. Jin L.-M., Lu H., Cui Y., Lizardi C. L., Arzua T. N., Wojtas L., Cui X., Zhang X. P. Selective radical amination of aldehydic C(sp<sup>2</sup>)–H bonds with fluoroaryl azides via Co(II)-based metalloradical catalysis: synthesis of *N*-fluoroaryl amides from aldehydes under neutral and nonoxidative conditions. *Chem. Sci.* 2014, **5**, 2422–2427.
16. Parra R. D., Zeng H., Zhu J., Zheng C., Zeng X. C., Gong B. Stable three-center hydrogen bonding in a partially rigidified structure. *Chem. Eur. J.* 2001, **7**, 4352–4357.
17. Karabulut S., Namli H., Kurtaran R., Yildirim L. T., Leszczynski J. Modeling the intermolecular interactions: molecular structure of N-3-hydroxyphenyl-4-methoxybenzamide. *J. Mol. Graph. Model.* 2014, **48**, 1–8.
18. Wigbers C., Prigge J., Mu Z., Fröhlich R., Chi L., Würthwein E.-U. Synthesis, structures, and aggregation properties of *N*-acylamidines. *Eur. J. Org. Chem.* 2011, **2011**, 861–877.
19. Wang M.-M., Nguyen T. V. T., Waser J. Diamine synthesis via the nitrogen-directed azidation of σ- and π-C–C bonds. *J. Am. Chem. Soc.* 2021, **143**, 11969–11975.
20. Ruan P., Tang Q., Yang Z., Liu X., Feng X. Enantioselective formal [2 + 2 + 2] cycloaddition of 1,3,5-triazinanes to construct tetrahydropyrimidin-4-one derivatives. *Chem. Commun.* 2022, **58**, 1001–1004.
21. Rauf M. K., Bolte M., Badshah A. 3-Chloro-*N*-cyclohexylbenzamide. *Acta Crystallogr.* 2009, **E65**, o1265.
22. Saeed A., Khera R. A., Abbas N., Flörke U. *N*-Cyclohexyl-3-fluorobenzamide. *Acta Crystallogr.* 2008, **E64**, o2209.